Boston Scientific/$BSX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Ticker
$BSX
Sector
Primary listing
NYSE
Employees
53,000
Headquarters
Website
BSX Metrics
BasicAdvanced
$149B
59.83
$1.68
0.66
-
Price and volume
Market cap
$149B
Beta
0.66
52-week high
$109.50
52-week low
$80.64
Average daily volume
11M
Financial strength
Current ratio
1.372
Quick ratio
0.645
Long term debt to equity
50.973
Total debt to equity
52.163
Interest coverage (TTM)
10.24%
Profitability
EBITDA (TTM)
4,705
Gross margin (TTM)
68.69%
Net profit margin (TTM)
13.55%
Operating margin (TTM)
18.98%
Effective tax rate (TTM)
16.73%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
5.39%
Return on equity (TTM)
11.55%
Valuation
Price to earnings (TTM)
59.835
Price to revenue (TTM)
8.023
Price to book
6.69
Price to tangible book (TTM)
-51
Price to free cash flow (TTM)
42.334
Free cash flow yield (TTM)
2.36%
Free cash flow per share (TTM)
2.375
Growth
Revenue change (TTM)
21.44%
Earnings per share change (TTM)
36.90%
3-year revenue growth (CAGR)
14.47%
10-year revenue growth (CAGR)
9.78%
3-year earnings per share growth (CAGR)
42.56%
10-year earnings per share growth (CAGR)
30.29%
What the Analysts think about BSX
Analyst ratings (Buy, Hold, Sell) for Boston Scientific stock.
Bulls say / Bears say
BSX raised its 2025 adjusted profit forecast to $2.95–$2.99 per share and trimmed the estimated tariff headwind to $100 million, reflecting confidence in offsetting cost pressures through robust sales growth and operational leverage (Reuters).
Boston Scientific reported Q2 adjusted EPS of $0.75 on revenue of $5.06 billion, beating analyst estimates and driven by strong demand for its Farapulse and Watchman heart rhythm devices (Reuters).
In Q2, the cardiovascular unit generated $3.34 billion in sales, underscoring the strength of BSX’s interventional cardiology portfolio and sustained market leadership in core growth segments (Reuters).
Early Alert: the FDA warned on August 6, 2025 that certain ENDOTAK RELIANCE defibrillation leads with calcified ePTFE‐coated coils have been linked to 386 serious injuries and 16 deaths, prompting recommendations for early replacement and posing significant safety and legal risks (FDA).
Recall: on July 7, 2025 Boston Scientific issued a removal letter for the Carotid WALLSTENT Monorail Endoprosthesis due to a manufacturing defect causing resistance upon device withdrawal, with six reported cases requiring additional interventions and potential stroke risk (FDA).
Product setback: on May 28, 2025 BSX halted global sales of its Acurate neo2 and Acurate Prime TAVR systems and will not pursue further regulatory approvals due to prohibitive requirements, marking a retreat from the structural heart market and potential revenue loss in that growth segment (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
BSX Financial Performance
Revenues and expenses
BSX Earnings Performance
Company profitability
BSX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Boston Scientific stock?
Boston Scientific (BSX) has a market cap of $149B as of October 21, 2025.
What is the P/E ratio for Boston Scientific stock?
The price to earnings (P/E) ratio for Boston Scientific (BSX) stock is 59.83 as of October 21, 2025.
Does Boston Scientific stock pay dividends?
No, Boston Scientific (BSX) stock does not pay dividends to its shareholders as of October 21, 2025.
When is the next Boston Scientific dividend payment date?
Boston Scientific (BSX) stock does not pay dividends to its shareholders.
What is the beta indicator for Boston Scientific?
Boston Scientific (BSX) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.